Rigel Pharmaceuticals Inc (RIGL)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

1180 VETERANS BOULEVARD SOUTH SAN FRANCISCO, CA 94080

Seeks to develop a portfolio of product candidates that can be developed into small molecule therapeutics. Placed two product candidates in clinical trials in 2004 and expects one additional product to enter clinical trials in 2005. Has collaborations with four major pharmaceutical companies.

Data as of 2021-05-08 10:29:17 -0400
Market Cap575.155 Million Shares Outstanding170.164 Million Avg 30-day Volume3.331 Million
P/E Ratio-50.07012 Dividend Yield EPS-0.067
Price/Sales4.3 Debt to Equity2.76 EBITDA-7.471 Million
Price to Book Value7.35 Forward PE-215.74 Enterprise Value555.654 Million
Total Cash39.345 Million Current Debt52.022 Million Gross Profit132.822 Million
BETA1.60581 52-week High/Low5.5 / 1.71 Next Earnings Date2021-08-03 Price to Cash FLow (P/CF) -9999999.0
Data provided by IEX Cloud
View SEC Filings from RIGL instead.
Q4 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 1 1 0.0% 1 (0.06%) 1 (0.06%) 0.0%
Funds Holding: 149 138 7.97% 49 (2.94%) 48 (2.99%) 2.08%
13F shares: 139.943 Million 139.767 Million 0.13% 54.836 Million 60.481 Million -9.33%
% Ownership 82.8154 82.7113 0.13% 32.4508 35.7913 -9.33%
New Positions: 26 22 18.18% 9 8 12.5%
Increased Positions 42 36 16.67% 9 16 -43.75%
Closed Positions 15 19 -21.05% 8 12 -33.33%
Reduced Positions 52 50 4.0% 23 20 15.0%
Total Calls 743.416 Thousand 438.829 Thousand 69.41% 270.1 Thousand 115.7 Thousand 133.45%
Total Puts 570.989 Thousand 694.3 Thousand -17.76% 104.5 Thousand 120.4 Thousand -13.21%
PUT/CALL Ratio 0.77 1.58 -51.27% 0.39 1.04 -62.5%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding RIGL (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding RIGL BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

RODRIGUEZ RAUL R CEO, PRESIDENT

  • Officer
  • Director
162,500 2021-04-01 2

VANCE DOLLY EVP CORP. AFFAIRS, G.C., SECT.

  • Officer
37,500 2021-04-01 2

SCHORNO DEAN L EVP &CHIEF FINANCIAL OFFICER

  • Officer
50,000 2021-04-01 2

DUMMER WOLFGANG EVP & CMO

  • Officer
0 2021-01-27 1

SANTOS DAVID A EVP, CHIEF COMMERCIAL OFFICER

  • Officer
0 2021-01-27 3

GOODWIN BRADFORD S

  • Director
0 2020-05-15 0

LYONS GARY A

  • Director
0 2020-05-15 0

MOOS WALTER H

  • Director
0 2020-05-15 0

KATKIN KEITH

  • Director
0 2020-05-15 0

KOTZIN BRIAN L.

  • Director
0 2020-05-15 0

LAPOINTE ANTHONY GREGG

  • Director
0 2020-05-15 0

WASMAN JANE

  • Director
0 2020-05-15 0

CABATUAN NELSON VP,FINANCE & PRINC.ACCTG. OFF.

  • Officer
0 2020-05-14 0

MAYER ELDON C. III EVP & CHIEF COMMERCIAL OFFICER

  • Officer
0 2019-11-18 0

LASAGA JOSEPH SR.VP BUS.DEV.ALLIANCE MGMT.

  • Officer
0 2019-11-18 0

MASUDA ESTEBAN SR. VP RESEARCH

  • Officer
0 2019-11-18 0

DULIEGE ANNE-MARIE EVP & CHIEF MEDICAL OFFICER

  • Officer
0 2019-03-20 0

MARKEL STACY EVP HUMAN RESOURCES

  • Officer
0 2019-03-20 0

RINGROSE PETER S

  • Director
0 2018-05-17 0

MAYNARD RYAN D EVP & CFO

  • Officer
0 2017-11-03 0

PAYAN DONALD G EVP, PRES. DISCOVERY&RESEARCH

  • Officer
  • Director
53,031 2016-08-30 0

SHERWIN STEPHEN A

  • Director
0 2016-05-11 0

GROSSBARD ELLIOTT B EVP, CMO

  • Officer
0 2016-01-26 0

GOWER JAMES M CEO & BOARD CHAIRMAN

  • Officer
  • Director
0 2014-02-27 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BVF INC/IL

LAMPERT MARK N

BIOTECHNOLOGY VALUE FUND II LP

BVF INVESTMENTS LLC

  • 10% Owner
  • SEE EXPLANATION OF RESPONSES SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
No longer subject to file 2013-11-19 0

RENTON HOLLINGS

  • Director
0 2013-05-15 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BVF INVESTMENTS LLC

INVESTMENT 10 LLC

BVF INC/IL

LAMPERT MARK N

  • 10% Owner
  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
9,697,997 2013-05-01 0

FLYNN JAMES E

DEERFIELD CAPITAL LP

DEERFIELD SPECIAL SITUATIONS FUND, L.P.

DEERFIELD PARTNERS, LP

DEERFIELD MANAGEMENT CO /NY

DEERFIELD SPECIAL SITUATIONS FUND INTERNATIONAL LTD

DEERFIELD INTERNATIONAL LTD

  • 10% Owner
  • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
No longer subject to file 2011-05-26 0

DELEAGE JEAN

  • Director
0 2010-05-28 0

COOPER ROBIN D G SR. V.P. PHARMACEUTICAL SCS.

  • Officer
0 2008-01-31 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

RODRIGUEZ RAUL R - Director - Officer CEO, PRESIDENT

2021-04-02 18:22:15 -0400 2021-04-01 A 162,500 a 162,500 direct

SCHORNO DEAN L - Officer EVP &CHIEF FINANCIAL OFFICER

2021-04-02 18:23:06 -0400 2021-04-01 A 50,000 a 50,000 direct

VANCE DOLLY - Officer EVP CORP. AFFAIRS, G.C., SECT.

2021-04-02 18:24:15 -0400 2021-04-01 A 37,500 a 37,500 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
RIGEL PHARMACEUTICALS INC RIGL 2021-05-14 22:15:03 UTC -0.3357 0.3857 1000000
RIGEL PHARMACEUTICALS INC RIGL 2021-05-14 21:45:03 UTC -0.3357 0.3857 1000000
RIGEL PHARMACEUTICALS INC RIGL 2021-05-14 21:15:03 UTC -0.3357 0.3857 1000000
RIGEL PHARMACEUTICALS INC RIGL 2021-05-14 20:45:03 UTC -0.3357 0.3857 1000000
RIGEL PHARMACEUTICALS INC RIGL 2021-05-14 20:15:04 UTC -0.3357 0.3857 1000000
RIGEL PHARMACEUTICALS INC RIGL 2021-05-14 19:45:02 UTC -0.3357 0.3857 1000000
RIGEL PHARMACEUTICALS INC RIGL 2021-05-14 19:15:03 UTC -0.3357 0.3857 1000000
RIGEL PHARMACEUTICALS INC RIGL 2021-05-14 18:45:03 UTC -0.3357 0.3857 1000000
RIGEL PHARMACEUTICALS INC RIGL 2021-05-14 18:15:03 UTC -0.3357 0.3857 1000000
RIGEL PHARMACEUTICALS INC RIGL 2021-05-14 17:45:03 UTC -0.3357 0.3857 1000000
RIGEL PHARMACEUTICALS INC RIGL 2021-05-14 17:15:03 UTC -0.3357 0.3857 1000000
RIGEL PHARMACEUTICALS INC RIGL 2021-05-14 16:45:03 UTC -0.3359 0.3859 1000000
RIGEL PHARMACEUTICALS INC RIGL 2021-05-14 16:15:03 UTC -0.3359 0.3859 1000000
RIGEL PHARMACEUTICALS INC RIGL 2021-05-14 15:45:03 UTC -0.3359 0.3859 1000000
RIGEL PHARMACEUTICALS INC RIGL 2021-05-14 15:15:02 UTC -0.3359 0.3859 1000000
RIGEL PHARMACEUTICALS INC RIGL 2021-05-14 14:45:04 UTC -0.3596 0.4096 1000000
RIGEL PHARMACEUTICALS INC RIGL 2021-05-14 14:15:03 UTC -0.3596 0.4096 950000
RIGEL PHARMACEUTICALS INC RIGL 2021-05-14 13:45:03 UTC -0.3596 0.4096 950000
RIGEL PHARMACEUTICALS INC RIGL 2021-05-14 13:15:03 UTC -0.3596 0.4096 1000000
RIGEL PHARMACEUTICALS INC RIGL 2021-05-14 12:45:03 UTC -0.3596 0.4096 950000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
RUSSELL INVESTMENT FUNDS- U.S. Small Cap Equity Fund RIGL -8560.0 shares, $-29960.0 2020-12-31 N-PORT

Elevate your investments